Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.82 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25836841 | 0.98 | EPHX1 (0.86) | EPHX1EPHX2CASP2 | |
| SCHEMBL8392636 | 0.98 | EPHX1 (0.86) | EPHX1EPHX2CASP2 | |
| SCHEMBL8848185 | 0.98 | EPHX1 (0.86) | EPHX1EPHX2CASP2 | |
| SCHEMBL25227718 | 0.98 | EPHX1 (0.86) | EPHX1EPHX2CASP2 | |
| SCHEMBL11236288 | 0.98 | EPHX1 (0.86) | EPHX1EPHX2CASP2 | |
| SCHEMBL25270954 | 0.98 | EPHX1 (0.86) | EPHX1EPHX2CASP2 | |
| SCHEMBL8391736 | 0.98 | EPHX1 (0.86) | EPHX1EPHX2CASP2 | |
| SCHEMBL25274521 | 0.98 | EPHX1 (0.86) | EPHX1EPHX2CASP2 | |
| SCHEMBL8392235 | 0.98 | EPHX1 (0.86) | EPHX1EPHX2CASP2 | |
| SCHEMBL969649 | 0.93 | EPHX1 (0.74) | EPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| WO-2018098204-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098209-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098206-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| EP-2927204-B1 | LIQUID PROPELLANT | CARLIT HOLDINGS CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-20150299063-A1 | LIQUID PROPELLANT | CARLIT HOLDINGS CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2927204-A1 | LIQUID PROPELLANT | Carlit Holdings Co. Ltd. (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | EPHX1 569/4885EPHX2 864/4885CASP2 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.